Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

By L. Beck, D. Thaçi, J. Hamilton, N. Graham, T. Bieber, R. Rocklin, J. Ming, H. Ren, R. Kao, E. Simpson and 9 more. New England Journal of Medicine, 2014

1,270 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Physiology

View Paper: https://www.semanticscholar.org/paper/c6d3afbb2e656761c8df381d476fed4686c35d2e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. K. Kabashima
2. C. Hsieh
3. Alexander Y. Rudensky

In Physiology

1. R. Gereau

Citations in the corpus

• Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch (2017, positive): “Notably, dupilumab, a recently approved monoclonal antibody that blocks both IL-4 and IL-13 signaling via their shared receptor subunit IL-4Ra, has demonstrated remarkable efficacy in treating AD (Beck et al., 2014; Simpson et al., 2016; Thaçi et al., 2016).”
• Atopic dermatitis (2018, background): “Acute AD lesions exhibit TH2-dominant inflammation characterized by dermal infiltration of CD4(1)T cells and eosinophils with deposition of eosinophil-derived products and increased skin expression of IL-4, IL-5, and IL-13.(57) A pathogenic role for IL-4 in the setting of AD is supported by the obse”